SMAC-derived peptides displace IAP from caspases, restoring apoptosis and overcoming chemotherapy resistance.
Fragmented water diluent boosts permeability, allowing glycine agents to neutralize odors without increasing surfactant toxicity.
A proteasome inhibitor targets the 20s beta5 subunit to treat ovarian clear cell carcinoma.
Combining HuLuc63 with bortezomib overcomes chemotherapy relapse by reducing tumor mass and improving long-term survival.
Ionizing radiation sterilizes dry solid S-nitrosothiols without reducing purity, overcoming degradation limits of conventional methods.
Combination therapies treat hepatitis C virus infections using specific compound pairs to reduce viral load.
PMI5011 regulates DUB activity in cancer cells without affecting viability, addressing heterogeneity and resistance challenges.
PSMA-targeting conjugates deliver therapeutic agents to prostate cancer cells, sparing non-target tissues from harmful side effects.